ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
124.83
+0.84 (+0.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close123.99
Open124.75
Bid124.90 x 100
Ask138.00 x 700
Day's Range122.63 - 125.50
52 Week Range35.98 - 147.63
Volume883,830
Avg. Volume1,154,509
Market Cap12.379B
Beta3.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch7 hours ago

    Alnylam stock more than tripled last year — and the company says 2018 will be big

    The company has a number of product launches, clinical trials and expansion plans in the works.

  • Motley Fool5 days ago

    Three Interviews From the J.P. Morgan Healthcare Conference

    We hear from executives from Alnylam, Arena Pharmaceuticals, and Spark Therapeutics at the biggest healthcare conference of the year.

  • Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
    Motley Fool6 days ago

    Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?

    There's a lot of good news potentially on the way for the biotech. But its 2017 performance will be hard to beat.

  • American City Business Journals8 days ago

    Alnylam CEO responds to Trump: ‘I’m proud to be a ‘s***holer!’’

    Trump's reported remarks about Haiti and some African countries during an Oval Office meeting with lawmakers on Thursday drew swift condemnation from prominent executives across a range of industries. Among them was Maraganore, who has led Alnylam (ALNY) for more than 15 years, and was appointed last year as chair of the Biotechnology Innovation Organization, or BIO. On Friday morning, Maraganore retweeted a New York Times story about Trump’s remarks, and wrote: “My Mom and Dad came to this country from what was then a ‘s***hole.’ They loved this country.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $1.21 billion.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
    Motley Fool10 days ago

    This Is Why Alnylam Pharmaceuticals Soared 249% in 2017

    It was a breakout year for the clinical-stage biotech.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
    Zacks12 days ago

    Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

    Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

  • Reuters13 days ago

    Sanofi to market new hemophilia drug in deal with Alnylam

    French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals. Under the agreement, Sanofi will obtain global development and commercialization rights to fitusiran, currently in development for the treatment of people with hemophilia A and B. Global commercialization of fitusiran will be done by Sanofi Genzyme, the specialty care global business unit of Sanofi, while Alnylam will receive royalties based on net sales of fitusiran products.

  • 5 of the Best-Performing Biotech Stocks of 2017
    Zacks23 days ago

    5 of the Best-Performing Biotech Stocks of 2017

    With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).

  • 4 Biotech Stocks That More Than Doubled This Year
    Zacks29 days ago

    4 Biotech Stocks That More Than Doubled This Year

    We take a look at a few biotech stocks whose price has increased more than 100% in 2017.

  • American City Business Journalslast month

    Insiders at these 25 Mass. firms netted $771M in stock sales this fall

    It’s been a good year to be an executive or director at a public company. The stock market is at all-time highs, as investors for months have been anticipating a giant windfall from the drastic lowering of the corporate tax rate. The Nasdaq Composite Index has spiked 28 percent over the past 12 months, while the Standard and Poor 500 is up 18 percent during that time.

  • Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?
    Zackslast month

    Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?

    Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.

  • Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
    Zackslast month

    Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy

    A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.

  • Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate
    Zackslast month

    Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

    Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

  • Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
    Zackslast month

    Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran

    Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.

  • The 3 Best Biotech Stocks of 2017
    Motley Foollast month

    The 3 Best Biotech Stocks of 2017

    What did it take to rank among the top three biotech stocks this year? At least a 440% gain.

  • Alnylam Gets Some Welcome News
    Motley Foollast month

    Alnylam Gets Some Welcome News

    A trial that had been on clinical hold because of a patient death has been cleared to restart.

  • Investor's Business Dailylast month

    The FDA Just Blessed A Hemophilia Trial From This Biotech

    Alnylam edged up Friday after the FDA lifted its clinical hold on trials of a hemophilia drug, allowing Alnylam to start administering the drug before year-end.

  • American City Business Journalslast month

    Alnylam gets FDA OK to restart hemophilia drug trial after patient's death

    Three months after Alnylam Pharmaceuticals halted trials of a hemophilia drug due to a patient's death, the Cambridge biotech has gotten permission from the FDA to resume studies. Alnylam (ALNY), one of the state’s largest and most valuable biotechs, stopped the Phase 2 and Phase 3 studies of fitusiran in September after one patient died of brain swelling triggered by a blood clot. The news sank shares of Alnylam, shaving $1 billion from its market cap.

  • The Wall Street Journallast month

    Stocks to Watch: CSX, Hess, Adobe, Costco, Aclaris Therapeutics

    Companies with shares expected to trade actively in Friday's session include CSX, Hess, Adobe Systems, Costco and Aclaris Therapeutics.

  • MarketWatchlast month

    Alnylam shares surge 5% after FDA lifts hold on hemophilia drug

    Alnylam Pharmaceuticals Inc. shares rose 5% in pre-market trade Friday after the company said the Food and Drug Administration has lifted a hold on clinical trials for hemophilia therapy fitusiran. Alnylam ...

  • Reuterslast month

    FDA allows Alnylam to restart hemophilia treatment trials

    The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday. All ongoing studies of the drug, fitusiran, had been placed on clinical hold after Alnylam suspended dosing following a patient death in one of the trials testing the drug in hemophilia patients. Alnylam said the FDA approved amended protocols related to the trials, and it expected to resume dosing patients around the end of the year.

  • Capital Cubelast month

    Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : December 11, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alnylam Pharmaceuticals, Inc. a score of 21. Our analysis is based on comparing Alnylam Pharmaceuticals, Inc. with the following peers – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Medicines Company, Sarepta Therapeutics, Inc., OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, ... Read more (Read more...)